Robert Azelby - Jan 2, 2024 Form 3 Insider Report for ADC Therapeutics SA (ADCT)

Role
Director
Signature
/s/ Ameet Mallik, as Attorney-in-Fact for Robert Azelby
Stock symbol
ADCT
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
3
Date filed
1/2/2024, 08:06 PM
Previous filing
Aug 11, 2023
Next filing
Mar 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ADCT Common Shares 20K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ADCT Stock Options (Right to Buy) Jan 2, 2024 Common Shares 31K $2.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Shares. The RSUs were granted on June 14, 2023 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.
F2 This option vests over four years from June 14, 2023, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney